Clinical Trials Browser

Phase 2 × OTHER × durvalumab × Clear all

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04668300 2026-04-15

DOSa

Phase 2 Active not recruiting

Hemangiosarcoma, Liposarcoma, Osteosarcoma

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06728410 2026-04-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05903092 2026-04-07

MOZART

Phase 2 Suspended

Small Cell Lung Carcinoma

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03589547 2026-04-02

358

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04245514 2026-04-02

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03795207 2026-03-31

POSTCARD

Phase 2 Active not recruiting

Node; Prostate

NCT04607954 2026-03-31

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

Platinum-Resistant Lung Small Cell Carcinoma

NCT04351256 2026-03-27

TRADE-hypo

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT07036380 2026-03-27

TACTIC

Phase 2 Recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT07489976 2026-03-27

IIT2025-03-YANG-LIFT-HCC

Phase 2 Recruiting

Hepato Cellular Carcinoma

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05696782 2026-03-23

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Phase 2 Completed

5 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Phase 2 Recruiting

Lung Neoplasms

NCT06859684 2026-03-09

HAIC-quad

Phase 2 Recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04602533 2026-02-27

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Phase 2 Active not recruiting

Lung Neoplasms

NCT04742075 2026-02-27

DOVACC

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06773910 2026-02-27

TIGOS-LS

Phase 2 Recruiting

Limited Stage Small Cell Lung Cancer

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT04945720 2026-02-25

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Phase 2 Completed

30 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

Lung Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07149363 2026-02-17

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03851614 2026-02-09

DAPPER

Phase 2 Active not recruiting

Leiomyosarcoma

NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Phase 2 Active not recruiting

Metastatic Malignant Female Reproductive System Neoplasm

NCT03141359 2026-02-05

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Phase 2 Active not recruiting

61 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06333678 2026-01-29

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Phase 2 Active not recruiting

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05206812 2026-01-27

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms